Indications for: VUMERITY
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Swallow whole. Initially 231mg twice daily for 7 days, then increase to maintenance dose of 462mg twice daily. If maintenance dose not tolerated, temporarily reduce back to initial dose. Within 4 weeks, resume maintenance dose; if not tolerated, consider discontinuing.
Concomitant dimethyl fumarate.
Obtain a CBC including lymphocyte count prior to initiation, after 6 months, and every 6–12 months thereafter; consider interruption if lymphocyte counts <0.5×109/L persist for >6 months. Pre-existing low lymphocyte counts: not studied. Monitor for herpes zoster, other serious opportunistic infections; evaluate and treat if occurs; consider withholding until infection resolved. Monitor serum aminotransferase, alkaline phosphatase, and total bilirubin prior to initiation and during treatment; discontinue if significant liver injury is suspected. Discontinue if anaphylaxis or angioedema occurs. Withhold and evaluate at first sign/symptom suggestive of PML. Administration with non-enteric coated aspirin (up to 325mg) or food may reduce incidence/severity of flushing. Moderate or severe renal impairment: not recommended. Pregnancy. Nursing mothers.
Avoid concomitant alcohol, high-fat and/or high-calorie meal/snack.
Flushing, abdominal pain, diarrhea, nausea, vomiting, pruritus, rash, albumin urine present; lymphopenia, liver injury.
Generic Drug Availability:
Del-rel caps—106 (Starter Pack), 120 (Maintenance Pack)